Michael Fons
Corporate Officer/Principal bij University of Texas Medical Branch
Profiel
Michael Fons is currently working as an Adjunct Associate Professor at the University of Texas Medical Branch.
Previously, he worked as an Executive Director-Business Development at Vical, Inc. from 2002 to 2004 and as a Vice President-Corporate Development at Inovio Pharmaceuticals, Inc.
Actieve functies van Michael Fons
| Bedrijven | Functie | Begin |
|---|---|---|
| University of Texas Medical Branch | Corporate Officer/Principal | - |
Eerdere bekende functies van Michael Fons
| Bedrijven | Functie | Einde |
|---|---|---|
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01-01-2004 |
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
